- Global Pharma News & Resources

OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs

Nantes, France – November 8, 2022, 6:00 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presents scientific updates in oral and poster presentations selected for international conferences: the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA,  November 8 – 12 and the Protein & Antibody Engineering Summit (PEGS) Europe 14th Annual Meeting in Barcelona, Spain, November 14 – 16. The communications feature the latest research on pre-IND programs from the pioneering Myeloid and BiCKI® platforms, namely presentations on OSE-230 (first pro-resolutive monoclonal antibody) in chronic inflammation, CLEC-1 (new myeloid immune checkpoint) and BiCKI®-IL-7 (new bifunctional therapy targeting PD-1 and IL-7) in immuno-oncology.

Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “We are very proud to share our latest scientific advances with the international scientific community on our innovative research platforms delivering next-generation first-in-class immunotherapies”.

Dr Aurore Morello, Head of Research of OSE Immunotherapeutics, explains: “The communications highlight the potential therapeutic value of our 3 pre-IND assets. BiCKI®-IL-7, our bispecific anti-PD1/IL-7 program, presents an innovative cytokine approach, selectively targeting tumor-specific T-cells to improve the quality and durability of memory T-lymphocyte responses. CLEC-1 is our novel myeloid checkpoint beyond the SIRPα/CD47 axis. OSE-230 stands as the first pro-resolutive agonist monoclonal antibody, capable to clear chronic neutrophil infiltrates and to inhibit the pathogenic NETosis* process and fibrosis”.

Myeloid Platform

OSE-230 program in the Resolution of Inflammation (PEGS Europe 2022)

Resolution of inflammation is triggered by pro-resolving lipids activating GPCRs (G-Protein Coupled Receptor) targets. The ChemR23 GPCR is expressed on inflammatory myeloid immune cells, such as macrophages and neutrophils, and is over-expressed in tissues affected by chronic inflammatory diseases, such as lung inflammatory diseases or severe IBD (Inflammatory Bowel Disease) unresponsive to anti-TNF or anti-integrin therapies. ChemR23’s over-expression is associated with chronic neutrophil accumulation in damaged tissues. OSE-230 is the first monoclonal antibody (mAb) to activate a pro-resolutive GPCR target (ChemR23). Its innovative mechanism of action drives inflammatory neutrophil tissue clearance through apoptosis and inhibition of the pathogenic NETosis* process. This mAb triggered resolution demonstrated positive preclinical efficacy in chronic colitis or chronic arthritis models with significant decrease in tissue fibrosis and restoration of tissue healing.

CLEC-1 program in Immuno-Oncology (SITC 2022)

CLEC-1 is a novel myeloid immune checkpoint beyond the SIRPα/CD47 axis inhibiting key functions of myeloid cells and hence limiting anti-tumor responsiveness of T-lymphocytes. Myeloid cells can accumulate in the tumor microenvironment and deregulate the immune activation of T-lymphocytes. The academic collaboration with Dr Elise Chiffoleau’s team** highlights that CLEC-1 inhibition represents a novel target for cancer immunotherapy. The latest data presented at the SITC 2022 show the ability of CLEC-1 to sense dead or stress tumor cells through the identification of a
CLEC-1 protein ligand (CLEC-1 ligand) over-expressed in cancer cells. Mechanistically, CLEC-1’s expression by dendritic cells controls the cross-presentation of dead-cell tumor associated antigens and hence CD8+ T-cell cross-priming. Reversely, the absence of CLEC-1 increases the phagocytosis of tumor cells by macrophages in vivo. Proprietary anti-CLEC-1 mAbs increase survival in monotherapy in orthotopic model of hepatocellular carcinoma while combination with chemotherapy increases preclinical tumor eradication in colon carcinoma model.

BiCKI® Platform

BiCKI®-IL-7 program in Immuno-Oncology (SITC 2022)

BiCKI®-IL-7, the most advanced candidate from the BiCKI® platform, is a bifunctional therapy which targets PD-1 and at the same time provides selectively the IL-7 pro-survival cytokine to PD1-expressing T-cells. BiCKI®-IL-7 restores exhausted T-cell function, disarms Treg suppressive activity and extends stem-like memory T-cells, the key T-cell subpopulation associated with anti-PD(L)1 clinical responses. This bifunctional immunotherapy preferentially delivers the IL-7 pro-survival cytokine to the right T-cells (tumor-specific T-cells expressing high level of PD1) and at the right place (PD1-expressing T-cells located in the tumor microenvironment and in the draining lymph nodes where the anti-tumor response is initiated and amplified). The latest data presented at the SITC 2022 show high IL-7 receptor (IL-7R) pathway expression in TILs (Tumor-Infiltrating Lymphocytes) and tumor-specific T-cell clonotypes, predictive of long-term ICI (Immune Checkpoint Inhibitor) clinical responses. Reversely, decreased IL-7R pathway expression is associated with metabolic stress and apoptosis of tumor-specific T-cells. Redirecting IL-7 selectively on PD1 + T-cells provides stemness, proliferative and survival signals to tumor-specific T-cells inducing durable responses. Additional data presented provides a strong rationale for selective delivery of IL-7 to tumor-specific T-cells to sustain long-lasting preclinical response, as well as selective proliferation and survival of stem-like memory T-cells in vivo.

SITC 2022 communications

  • Title: IL7R TME expression correlates with immunotherapy response and is associated with T-cell stemness with decreased apoptosis” (abstract #826), poster presentation by I. Girault et al.
  • Title: Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T-cells expansion and long-lasting in-vivo efficacy”(abstract #1366), poster presentation by A. Morello et al.
  • Title: Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen cross-presentation” (abstract #484), poster presentation by V. Gauttier, I. Baccelli et al.

PEGS 2022 communication

  • Title: “Agonist Anti-ChemR23 Antibody for Inflammatory Diseases, oral presentation in the session “Biotherapeutics for GPCR Targets” on November 16th at 5:30pm by N. Poirier.

* NETosis is a program for formation of neutrophil extracellular traps (NETs), which consists of modified chromatin decorated with bactericidal proteins from granules and cytoplasm. Recent research has highlighted that neutrophils, and in particular NETs that can be released upon activation, have central roles in the initiation and perpetuation of systemic autoimmune disorders and trigger complex and chronic inflammatory responses that lead to organ damage and fibrosis.

** Collaborative academic program between OSE Immunotherapeutics and Dr Elise Chiffoleau’s research teams (Center for Research in Transplantation and Translational Immunology (CR2TI), UMR1064, INSERM, Nantes University at Nantes University Hospital,

Editor Details

Related Links

Last Updated: 09-Nov-2022